Treatment of IgA nephropathy! Novartis AG Sponsored ADR (NVS.US) Avacopan is expected to be included in priority review.

On November 12th, the official website of CDE showed that the hydrochloride of Acurastan tablets sponsored by Novartis AG Sponsored ADR (NVS. US) is planned to be included in the priority review, indicated for the treatment of proteinuria in adult patients with primary IgA nephropathy (IgAN) to reduce the risk of disease progression. Public information indicates that Acurastan is a potent selective oral ETA (endothelin A) receptor antagonist under research. Activation of the ETA receptor can lead to an increase in proteinuria, which is related to kidney damage, fibrosis, and loss of kidney function in IgAN. Acurastan may be added to current supportive therapy to reduce persistent proteinuria and protect the kidney function of a large group of patients. Preclinical models also suggest that Acurastan can reduce inflammation and fibrosis in IgAN. It is worth noting that another new drug, hydrochloride of Ippopen capsules sponsored by Novartis AG Sponsored ADR, has recently submitted a new indication application for IgAN in China (JXHS2400053). This drug is the world's first approved complement pathway inhibitor for decreasing proteinuria in primary IgA nephropathy (IgAN) with a risk of rapid progression, and is expected to accelerate the expansion of indications for IgAN and other kidney diseases based on the approved indication for paroxysmal nocturnal hemoglobinuria (PNH) in China, bringing more targeted treatment options for Chinese IgAN patients.